Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. PAREXEL INTERNATIONAL, Corp
EIR
•PAREXEL INTERNATIONAL, Corp•July 15, 2019

PAREXEL INTERNATIONAL, Corp – FDA EIR, Jul 15, 2019

Record Details

An FDA Bioresearch Monitoring (BIMO) inspection was conducted at Parexel's Billerica, MA facility between July 11 and July 15, 2019. This high-priority review, initiated under Compliance Program 7348.810, assessed Parexel's operations as a Contract Research Organization (CRO) supporting Tesaro, Inc.'s clinical study protocol PR-30-5020-C (QUADRA). The study focused on the safety and efficacy of niraparib for ovarian cancer, and the inspection formed part of a Supplemental New Drug Application (sNDA) process, emphasizing data integrity and Good Clinical Practice. The scope of the review included Parexel's policies, study registration, quality assurance processes, endpoint data verification, record retention, and electronic record management systems.

The inspection concluded without the issuance of a Form FDA-483 or any formal regulatory violations, indicating a generally compliant state. No samples were collected, and the firm cooperated fully. One discussion item was brought to management's attention regarding discrepancies in the effective dates and signature dates for the Master Service Agreement (MSA) and Statement of Work (SOW) governing Parexel's services. The effective dates for these documents predated their actual signature dates. Parexel was cautioned that commencing study-related work prior to formalized contractual signatures could potentially result in future FDA Inspectional Observations. This serves as a professional advisory emphasizing the need for meticulous adherence to documentation timelines within the regulatory framework.

Company
PAREXEL INTERNATIONAL, Corp
Inspection date
July 15, 2019
Product type
drugs
Office
New England District Office
People
  • Martin Preis (company_representative)
  • Jamie Macdonald (recipient)
  • Lindsey J. Klane (company_representative)
  • Debra Ainge (company_representative)
  • Elina Tebelekian (company_representative)
View Company Profile

ID · 14247480-6ecf-41a2-9fda-ee64aa97d535

Violation Codes1
21 CFR 312

Full citation text and observation details available on the Dashboard.

Other documents for PAREXEL INTERNATIONAL, Corp
  • EIR - 2020-08-05August 5, 2020

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore PAREXEL INTERNATIONAL, Corp
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.